Medicare Enrolled
Dr. Natalie Marshall, M.D.
Medical Oncology · Berkeley, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Marshall from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Marshall?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Marshall
Dr. Natalie Marshall is a medical oncology specialist in Berkeley, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Marshall performed 20,487 Medicare services across 1,025 unique beneficiaries.
Between the years covered by Open Payments, Dr. Marshall received a total of $4,966 from 38 pharmaceutical and/or device companies across 295 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Marshall is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 16% volume in CA
$4,966 industry payments
Medicare Practice Summary
Medicare Utilization ↗20,487
Medicare services
Top 16% in CA for medical oncology
1,025
Unique beneficiaries
$15
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,024 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (aprepitant) | 7,930 | $1 | $27 |
| Denosumab injection (Prolia/Xgeva) | 6,480 | $18 | $148 |
| Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg | 1,280 | $10 | $344 |
| Anti-nausea injection (Aloxi/palonosetron) | 840 | $1 | $46 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
713 | $2 | $52 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
534 | $16 | $140 |
| Anti-nausea injection (ondansetron/Zofran) | 496 | $0 | $2 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
390 | $115 | $577 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
316 | $139 | $1,079 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
163 | $8 | $22 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
160 | $13 | $139 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
159 | $7 | $355 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
149 | $8 | $81 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
135 | $10 | $69 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
107 | $156 | $773 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
104 | $34 | $314 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
86 | $68 | $481 |
| New patient office visit, complex (60-74 min) | 85 | $198 | $1,085 |
| 5% dextrose/water (500 ml = 1 unit) | 71 | $1 | $50 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
64 | $66 | $393 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
64 | $1 | $22 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
58 | $13 | $92 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
39 | $37 | $346 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
32 | $28 | $169 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
32 | $29 | $200 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
5.4% high complexity
88.4% medium
6.1% routine
Industry Payment Transparency
Open Payments through 2022 ↗$4,966
Total received (2018-2022)
Avg $993/year across 5 years
Top 50% in CA for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
38
Companies
295
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,675 (94.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$290 (5.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2022
$46
2021
$101
2020
$48
2019
$2,280
2018
$2,492
Payments by company (2022)
Consulting
Speaking
Meals & Travel
Research
Acrotech Biopharma LLC
$26
Boehringer Ingelheim Pharmaceuticals, Inc.
$20
Top 3 companies account for 100.0% of 2022 payments
All-time payments by company (2018-2022) ›
Novartis Pharmaceuticals Corporation
$697
PFIZER INC.
$384
Astellas Pharma US Inc
$342
E.R. Squibb & Sons, L.L.C.
$337
Janssen Biotech, Inc.
$336
Merck Sharp & Dohme Corporation
$311
Genentech USA, Inc.
$272
TESARO, Inc.
$262
Amgen Inc.
$247
AstraZeneca Pharmaceuticals LP
$245
Pharmacyclics LLC, An AbbVie Company
$174
Takeda Pharmaceuticals U.S.A., Inc.
$123
Clovis Oncology, Inc.
$122
Seattle Genetics, Inc.
$110
Bayer HealthCare Pharmaceuticals Inc.
$105
Daiichi Sankyo Inc.
$89
Celgene Corporation
$86
GENZYME CORPORATION
$81
TerSera Therapeutics LLC
$60
Eisai Inc.
$59
Alexion Pharmaceuticals, Inc.
$50
Taiho Oncology, Inc.
$50
AbbVie, Inc.
$46
Teva Pharmaceuticals USA, Inc.
$40
Helsinn Therapeutics (U.S.), Inc.
$38
Boehringer Ingelheim Pharmaceuticals, Inc.
$37
R-Pharm US LLC
$34
Janssen Pharmaceuticals, Inc
$29
Acrotech Biopharma LLC
$26
Spectrum Pharmaceuticals Inc.
$24
Lilly USA, LLC
$24
EISAI INC.
$23
Exelixis Inc.
$22
SANOFI-AVENTIS U.S. LLC
$22
Lexicon Pharmaceuticals, Inc.
$17
Foundation Medicine, Inc.
$15
Kyowa Kirin, Inc.
$15
Gilead Sciences, Inc.
$12
Top 3 companies account for 28.6% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AKYNZEO · Abraxane · Alecensa · Avastin · BELEODAQ · BENDEKA · BRAFTOVI · CABLIVI · Cabometyx · DARZALEX · ELIQUIS · ELITEK · EMPLICITI · ERBITUX · ERLEADA · FARESTON · FOUNDATIONONE · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INFLECTRA · INJECTAFER · INLYTA · Imbruvica · Inrebic · Ixempra · JADENU · JEVTANA · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LYNPARZA · Lenvima · Lonsurf · MEKINIST · NINLARO · Neulasta · Nplate · OPDIVO · PIQRAY · PROMACTA · Perjeta · RYDAPT · Revlimid · Rubraca · SANDOSTATIN · SOLIRIS · SPEVIGO · SUTENT · Stivarga · TAGRISSO · TASIGNA · TECENTRIQ · ULTOMIRIS · VENCLEXTA · VOTRIENT · Venclexta · Vitrakvi · XALKORI · XARELTO · XOSPATA · XTANDI · Xermelo · Xofigo · ZEJULA · ZOLADEX · ZYTIGA · Zevalin
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (94%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Medical oncologists within 10 mi
33
Per 100K population
2.0
County median income
$126,240
Nearest hospital
ALTA BATES SUMMIT MEDICAL CENTER
2.5 mi
2.5 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2022 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Marshall is a mixed practice specialist, with above-average Medicare volume (top 16% in CA), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Marshall experienced with anti-nausea injection (aprepitant)?
Based on Medicare claims data, Dr. Marshall performed 7,930 anti-nausea injection (aprepitant) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Marshall receive payments from pharmaceutical companies?
Yes. Dr. Marshall received a total of $4,966 from 38 companies across 295 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Marshall's costs compare to other medical oncologists in Berkeley?
Dr. Marshall's average Medicare payment per service is $15. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Marshall) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Berkeley
Browse medical oncologists in Berkeley ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in CA
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in CA
Which CA medical oncologists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Astellas Pharma US Inc Payments to Doctors
See all physicians who received payments from Astellas Pharma US Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology